{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:34:42Z","timestamp":1791009282856,"version":"4.1.0"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C2005057"],"award-info":[{"award-number":["NRF-2022R1A2C2005057"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell leukemia or lymphoma. Unfortunately, many challenges remain to be addressed to overcome its ineffectiveness in the treatment of other hematological and solidtumor malignancies. The major hurdles of CAR T-cell therapy are the associated severe life-threatening toxicities such as cytokine release syndrome and limited anti-tumor efficacy. In this review, we briefly discuss cancer immunotherapy and the genetic engineering of T cells and, In detail, the current innovations in CAR T-cell strategies to improve efficacy in treating solid tumors and hematologic malignancies. Furthermore, we also discuss the current challenges in CAR T-cell therapy and new CAR T-cell-derived nanovesicle therapy. Finally, strategies to overcome the current clinical challenges associated with CAR T-cell therapy are included as well.<\/jats:p>","DOI":"10.3389\/fimmu.2022.925985","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:11:06Z","timestamp":1658491866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":208,"title":["CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments"],"prefix":"10.3389","volume":"13","author":[{"given":"Manasi P.","family":"Jogalekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya Lakshmi","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crismita","family":"Dmello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Gangadaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Cheol","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of pd-1\/pd-l1 blockade via combination therapy and pd-l1regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"150923","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: the history and background of immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions","volume":"14","author":"Handy","year":"2018","journal-title":"Future Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082492","article-title":"Blockade of ctla-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-ctla-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1129478","article-title":"Ipilimumab(anti-ctla-4 mab) in the treatment of metastatic melanoma: effectiveness and toxicity management","volume":"12","author":"Savoia","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of aki: where do we stand","volume":"11","author":"Franzin","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and pd-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The pd-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5474602","article-title":"CAR T cell therapy: a game changer in cancer treatment","volume":"2016","author":"Alm\u00e5sbak","year":"2016","journal-title":"J Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat Rev Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering car-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of hla class i, class ii, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.40","article-title":"The hyperactive sleeping beauty transposase sb100x improves the genetic modification of T cells to express a chimeric antigen receptor","volume":"18","author":"Jin","year":"2011","journal-title":"Gene Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01717","article-title":"Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells","volume":"9","author":"Elahi","year":"2018","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/sj.gt.3302648","article-title":"Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories","volume":"13","author":"Przybylowski","year":"2006","journal-title":"Gene Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"B21","first-page":"1","article-title":"Viral vectors: a look back and ahead on gene transfer technology","volume":"36","author":"Vannucci","year":"2013","journal-title":"New Microbiol"},{"key":"B22","unstructured":"Home - ClinicalTrials.Gov"},{"key":"B23","doi-asserted-by":"publisher","first-page":"E674","DOI":"10.3390\/cancers11050674","article-title":"Car T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor cxcr2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting b7-h3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"E2567","DOI":"10.3390\/cancers12092567","article-title":"The landscape of car-T cell clinical trials against solid tumors-a comprehensive overview","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed car T cells for advanced metastasis malignancies: a phase i trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000079824","article-title":"Expression of cd24 in adenocarcinomas of the pancreas correlates with higher tumor grades","volume":"4","author":"Jacob","year":"2004","journal-title":"Pancreatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602232","article-title":"MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)bi-c595 radioimmunoconjugate","volume":"91","author":"Qu","year":"2004","journal-title":"Br J Cancer"},{"key":"B29","article-title":"Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma","volume":"61","author":"Argani","year":"2001","journal-title":"Cancer Res"},{"key":"B30","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T cells targeting the tumor muc1 glycoprotein reduce triple-negative breast cancer growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated nkg2d car T cells","volume":"11","author":"Han","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00262-017-2089-5","article-title":"Targeting and suppression of her3-positive breast cancer by t lymphocytes expressing a heregulin chimeric antigen receptor","volume":"67","author":"Zuo","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E1797","DOI":"10.3390\/ijms18091797","article-title":"Human cd3+ T-cells with the anti-erbb2 chimeric antigen receptor exhibit efficient targeting and induce apoptosis in erbb2 overexpressing breast cancer cells","volume":"18","author":"Munisvaradass","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2008","article-title":"CAR T therapy targeting icam-1 eliminates advanced human thyroid tumors","volume":"23","author":"Min","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00202069","article-title":"Intercellular adhesion molecule-1","volume":"74","author":"van de Stolpe","year":"1996","journal-title":"J Mol Med (Berl)"},{"key":"B39","article-title":"Soluble intracellular adhesion molecules (sicam-1, svcam-1) in peripheral blood of patients with thyroid cancer","volume":"51","author":"Pasieka","year":"2004","journal-title":"Neoplasma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular wilms tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.01.012","article-title":"Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting gdnf family receptor alpha 4","volume":"20","author":"Bhoj","year":"2021","journal-title":"Mol Ther Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused egfrviii-directed car T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao2731","article-title":"Constitutive and tnf\u03b1-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: implications for car-T cell therapy","volume":"10","author":"Pellegatta","year":"2018","journal-title":"Sci Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted cd4+ car T cells mediate superior antitumor activity","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or cxcr2-modified car T cells co-opt il-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting bites circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123815","article-title":"B7-H3 chimeric antigen receptor redirected T cells target anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"12","author":"Zi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02683","article-title":"CAR-engineered nk cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy","volume":"10","author":"Burger","year":"2019","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7263","article-title":"The efficacy of third generation anti\u2212her2 chimeric antigen receptor T cells in combination with pd1 blockade against malignant glioblastoma cells","volume":"42","author":"Shen","year":"2019","journal-title":"Oncol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416","article-title":"Tandem car T cells targeting her2 and il13r\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","article-title":"Optimizing . epha2-car T cells for the adoptive immunotherapy of glioma","volume":"9","author":"Yi","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent car T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2672","article-title":"Chlorotoxin-directed car T cells for specific and effective targeting of glioblastoma","volume":"12","author":"Wang","year":"2020","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: A Cancer J Clin"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous cd19-targeted T cells in patients with relapsed or chemotherapy refractory b-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-cd19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.3390\/cancers11010047","article-title":"Chimeric antigen receptor T-cell (car T) therapy for hematologic and solid malignancies: efficacy and safety-a systematic review with meta-analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: cars take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous t-lymphocytes genetically retargeted against carbonic anhydrase ix: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived cd19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (car) t therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (sgn-35) for relapsed cd30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (sgn-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein barr virus specific cytotoxic t lymphocytes expressing the anti-cd30zeta artificial chimeric T-cell receptor for immunotherapy of hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199911000-00001","article-title":"Characterization of a chimeric T-cell receptor with specificity for the hodgkin\u2019s lymphoma-associated cd30 antigen","volume":"22","author":"Hombach","year":"1999","journal-title":"J Immunother"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing ccr4 and a chimeric antigen receptor targeting cd30 have improved homing and antitumor activity in a hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.185.185","article-title":"Chimeric T cells for therapy of cd30+ hodgkin and non-hodgkin lymphomas","volume":"126","author":"Ramos","year":"2015","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing cd30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B77","unstructured":"Lymphoma Research FoundationAbout Lymphoma"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous cd20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred cd20\/cd19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of b-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize cd19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both cd28 and 4-1bb domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"New Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large b-cell lymphoma and indolent b-cell malignancies can be effectively treated with autologous T cells expressing an anti-cd19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"JCO"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing cd19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 car-T cells of defined cd4+:cd8+ composition in adult b cell all patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B86","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-hodgkin\u2019s lymphoma with a defined ratio of cd8+ and cd4+ cd19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-cd19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"JCO"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-cd19 chimeric antigen receptor induce remissions of b-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate cd19-specific car T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of zuma-1: a multicenter study of kte-c19 anti-cd19 car T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.581.581","article-title":"High durable cr rates in relapsed\/refractory (r\/r) aggressive b-nhl treated with the cd19-directed car T cell product jcar017 (transcend nhl 001): defined composition allows for dose-finding and definition of pivotal cohort","volume":"130","author":"Abramson","year":"2017","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the cd19-targeted therapy ctl019 in adult patients with relapsed or refractory (r\/r) diffuse large b-cell lymphoma (dlbcl)\u2014an interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large b-cell lymphoma treated by cd20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of cd20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory b-cell non-hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Sig Transduct Target Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311845","article-title":"In Vitro and In Vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-cd23 chimeric antigen receptor","volume":"117","author":"Giordano Attianese","year":"2011","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ror1 can be targeted with T cells modified to express a ror1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-020-00391-y","article-title":"Immunophenotypic and molecular analysis of a b cell lymphoma with discordant light chain expression at different anatomic sites","volume":"13","author":"Galeano","year":"2020","journal-title":"J Hematopathol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-cd22-chimeric antigen receptors targeting b-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.8.2081.2081","article-title":"Interleukin-2 treatment in lymphoma: a phase ii multicenter study","volume":"83","author":"Gisselbrecht","year":"1994","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor t-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol Rev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3558","article-title":"A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000190","article-title":"T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia","volume":"22","author":"Mardiros","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells In Vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.blre.2014.09.011","article-title":"The development of potential antibody-based therapies for myeloma","volume":"29","author":"Sherbenou","year":"2015","journal-title":"Blood Rev"},{"key":"B108","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3010","article-title":"First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Updated results","volume":"35","author":"Berdeja","year":"2017","journal-title":"JCO"},{"key":"B113","doi-asserted-by":"publisher","first-page":"LBA3001","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001","article-title":"Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma","volume":"35","author":"Fan","year":"2017","journal-title":"JCO"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.02.007","article-title":"Graft-versus-host disease after donor leukocyte infusions: presentation and management","volume":"21","author":"Frey","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.070","article-title":"Treatment of advanced leukemia in mice with mRNA engineered T cells","volume":"22","author":"Barrett","year":"2011","journal-title":"Hum Gene Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2351","article-title":"Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation","volume":"101","author":"Marktel","year":"2003","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12216","article-title":"Cd3\u03b6-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy","volume":"175","author":"Bridgeman","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"B136","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector functionn In Vitro paradoxically impairs the In Vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1080\/08820130600745430","article-title":"Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy","volume":"35","author":"Fisher","year":"2006","journal-title":"Immunol Invest"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"B141","doi-asserted-by":"publisher","first-page":"E442","DOI":"10.3390\/pharmaceutics12050442","article-title":"Extracellular vesicle- and extracellular vesicle mimetics-based drug delivery systems: new perspectives, challenges, and clinical developments","volume":"12","author":"Gangadaran","year":"2020","journal-title":"Pharmaceutics"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112146","article-title":"vesicles derived from macrophage promote angiogenesis In vitro and accelerate new vasculature formation In Vivo","volume":"394","author":"Gangadaran","year":"2020","journal-title":"Exp Cell Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14050","article-title":"Human fibroblast-derived extracellular vesicles promote hair growth in cultured human hair follicles","volume":"595","author":"Rajendran","year":"2021","journal-title":"FEBS Lett"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040495","article-title":"Identification of angiogenic cargo in extracellular vesicles secreted from human adipose tissue-derived stem cells and induction of angiogenesis In Vitro and In Vivo","volume":"13","author":"Gangadaran","year":"2021","journal-title":"Pharmaceutics"},{"key":"B145","doi-asserted-by":"publisher","first-page":"E856","DOI":"10.3390\/cells9040856","article-title":"Macrophage-derived extracellular vesicle promotes hair growth","volume":"9","author":"Rajendran","year":"2020","journal-title":"Cells"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2021.08.006","article-title":"Intercellular communication through extracellular vesicles in cancer and evolutionary biology","volume":"165","author":"Bonner","year":"2021","journal-title":"Prog Biophysics Mol Biol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12964-021-00787-y","article-title":"Extracellular vesicles: mediators of intercellular communication in tissue injury and disease","volume":"19","author":"Berumen S\u00e1nchez","year":"2021","journal-title":"Cell Communication Signaling"},{"key":"B148","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5483\/BMBRep.2022.55.1.075","article-title":"The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer","volume":"55","author":"Hong","year":"2022","journal-title":"BMB Rep"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-018-9000-0","article-title":"Role of T cell-derived exosomes in immunoregulation","volume":"66","author":"Lu","year":"2018","journal-title":"Immunol Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-020-01278-3","article-title":"Exosome-based immunotherapy: a promising approach for cancer treatment","volume":"19","author":"Xu","year":"2020","journal-title":"Mol Cancer"},{"key":"B151","unstructured":"Natural-killer-derived extracellular vesicles: immune sensors and interactors\n            FedericiC\n            ShahajE\n            CecchettiS\n            CameriniS\n            CasellaM\n            IessiE\n          2020"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00352-2","article-title":"Cytokine-enhanced cytolytic activity of exosomes from NK Cells","volume":"29","author":"Enomoto","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"B154","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13578-020-00427-x","article-title":"Extracellular vesicles derived from different sources of mesenchymal stem cells: therapeutic effects and translational potential","volume":"10","author":"Cai","year":"2020","journal-title":"Cell Biosci"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42998","article-title":"Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"key":"B156","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13046-020-01586-y","article-title":"Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy","volume":"39","author":"Galli","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061401","article-title":"CD19 chimeric antigen receptor-exosome targets cd19 positive b-lineage acute lymphocytic leukemia and induces cytotoxicity","volume":"13","author":"Haque","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.192","article-title":"Extracellular vesicles derived from chimeric antigen receptor-T cells: a potential therapy for cancer","volume":"32","author":"Aharon","year":"2021","journal-title":"Hum Gene Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090727","article-title":"Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis","volume":"24","author":"Ma","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301685","article-title":"Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes In Vitro lymphocyte survival in pro-apoptotic conditions","volume":"9","author":"Eaton","year":"2002","journal-title":"Gene Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy In Vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-cd19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.999.999","article-title":"T cells expressing a novel fully-human anti-cd19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial","volume":"128","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the btk inhibitor ibrutinib to anti-cd19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"B171","doi-asserted-by":"publisher","first-page":"E340","DOI":"10.3390\/ijms19020340","article-title":"Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T","volume":"19","author":"Yoon","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.167","article-title":"Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies","volume":"23","author":"Kebriaei","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.2","article-title":"A transposon and transposase system for human application","volume":"18","author":"Hackett","year":"2010","journal-title":"Mol Ther"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593","article-title":"Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors","volume":"95","author":"Krishnan","year":"2000","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.925985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:11:15Z","timestamp":1658491875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.925985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":174,"alternative-id":["10.3389\/fimmu.2022.925985"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.925985","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"article-number":"925985"}}